Literature DB >> 25369767

Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.

Óscar Cordero-Llana1, Benjamin C Houghton1, Federica Rinaldi1, Hannah Taylor1, Rafael J Yáñez-Muñoz2, James B Uney3, Liang-Fong Wong3, Maeve A Caldwell3.   

Abstract

Cerebral Dopamine Neurotrophic Factor (CDNF) and Mesencephalic Astrocyte-derived Neurotrophic factor (MANF) are members of a recently discovered family of neurotrophic factors (NTFs). Here, we used intranigral or intrastriatal lentiviral vector-mediated expression to evaluate their efficacy at protecting dopaminergic function in the 6-OHDA model of Parkinson's disease (PD). In contrast to the well-studied Glial-Derived Neurotrophic Factor (GDNF), no beneficial effects were demonstrated by striatal overexpression of either protein. Interestingly, nigral overexpression of CDNF decreased amphetamine-induced rotations and increased tyroxine hydroxylase (TH) striatal fiber density but had no effect on numbers of TH(+) cells in the SN. Nigral MANF overexpression had no effect on amphetamine-induced rotations or TH striatal fiber density but resulted in a significant preservation of TH(+) cells. Combined nigral overexpression of both factors led to a robust reduction in amphetamine-induced rotations, greater increase in striatal TH-fiber density and significant protection of TH(+) cells in the SN. We conclude that nigral CDNF and MANF delivery is more efficacious than striatal delivery. This is also the first study to demonstrate that combined NTF can have synergistic effects that result in enhanced neuroprotection, suggesting that multiple NTF delivery may be more efficacious for the treatment of PD than the single NTF approaches attempted so far.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25369767      PMCID: PMC4445614          DOI: 10.1038/mt.2014.206

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

Review 1.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

2.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

Review 3.  The GDNF family: signalling, biological functions and therapeutic value.

Authors:  Matti S Airaksinen; Mart Saarma
Journal:  Nat Rev Neurosci       Date:  2002-05       Impact factor: 34.870

4.  GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Authors:  Mickael Decressac; Ayse Ulusoy; Bengt Mattsson; Biljana Georgievska; Marina Romero-Ramos; Deniz Kirik; Anders Björklund
Journal:  Brain       Date:  2011-06-28       Impact factor: 13.501

5.  Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

Authors:  Biljana Georgievska; Deniz Kirik; Carl Rosenblad; Cecilia Lundberg; Anders Björklund
Journal:  Neuroreport       Date:  2002-01-21       Impact factor: 1.837

Review 6.  Trophic factor gene therapy for Parkinson's disease.

Authors:  Jeffrey H Kordower; Anders Bjorklund
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

7.  Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

Authors:  Päivi Lindholm; Merja H Voutilainen; Juha Laurén; Johan Peränen; Veli-Matti Leppänen; Jaan-Olle Andressoo; Maria Lindahl; Sanna Janhunen; Nisse Kalkkinen; Tõnis Timmusk; Raimo K Tuominen; Mart Saarma
Journal:  Nature       Date:  2007-07-05       Impact factor: 49.962

8.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

9.  MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain.

Authors:  Päivi Lindholm; Johan Peränen; Jaan-Olle Andressoo; Nisse Kalkkinen; Zaal Kokaia; Olle Lindvall; Tõnis Timmusk; Mart Saarma
Journal:  Mol Cell Neurosci       Date:  2008-07-30       Impact factor: 4.314

10.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Authors:  J G Nutt; K J Burchiel; C L Comella; J Jankovic; A E Lang; E R Laws; A M Lozano; R D Penn; R K Simpson; M Stacy; G F Wooten
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

View more
  23 in total

1.  MANF deletion abrogates early larval Caenorhabditis elegans stress response to tunicamycin and Pseudomonas aeruginosa.

Authors:  Jessica H Hartman; Christopher T Richie; Kacy L Gordon; Danielle F Mello; Priscila Castillo; April Zhu; Yun Wang; Barry J Hoffer; David R Sherwood; Joel N Meyer; Brandon K Harvey
Journal:  Eur J Cell Biol       Date:  2019-05-21       Impact factor: 4.492

Review 2.  Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.

Authors:  Tingting Tang; Yong Li; Qian Jiao; Xixun Du; Hong Jiang
Journal:  Neurosci Bull       Date:  2017-03-23       Impact factor: 5.203

3.  Cerebral dopamine neurotrophic factor protects H9c2 cardiomyocytes from apoptosis.

Authors:  H Liu; C Yu; H Yu; L Zhong; Y Wang; J Liu; S Zhang; J Sun; L Duan; L Gong; J Yang
Journal:  Herz       Date:  2017-04-25       Impact factor: 1.443

4.  The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.

Authors:  Cristiane Latge; Katia M S Cabral; Guilherme A P de Oliveira; Diana P Raymundo; Julia A Freitas; Laizes Johanson; Luciana F Romão; Fernando L Palhano; Torsten Herrmann; Marcius S Almeida; Debora Foguel
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

Review 5.  Potential Role of MANF, an ER Stress Responsive Neurotrophic Factor, in Protecting Against Alcohol Neurotoxicity.

Authors:  Wen Wen; Hui Li; Jia Luo
Journal:  Mol Neurobiol       Date:  2022-03-07       Impact factor: 5.590

6.  The lentiviral-mediated Nurr1 genetic engineering mesenchymal stem cells protect dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Xiaoxiao Wang; Wenxin Zhuang; Wenyu Fu; Xiaocui Wang; E Lv; Fengjie Li; Shuanhu Zhou; Wolf-Dieter Rausch; Xin Wang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

7.  Expression and Distribution of Mesencephalic Astrocyte-Derived Neurotrophic Factor in the Retina and Optic Nerve.

Authors:  Feng-Juan Gao; Sheng-Hai Zhang; Ting-Ting Li; Ji-Hong Wu; Qiang Wu
Journal:  Front Hum Neurosci       Date:  2017-01-19       Impact factor: 3.169

8.  Recombinant AAV8-mediated intrastriatal gene delivery of CDNF protects rats against methamphetamine neurotoxicity.

Authors:  Lizheng Wang; Zixuan Wang; Xiaoyu Xu; Rui Zhu; Jinpeng Bi; Wenmo Liu; Xinyao Feng; Hui Wu; Haihong Zhang; Jiaxin Wu; Wei Kong; Bin Yu; Xianghui Yu
Journal:  Int J Med Sci       Date:  2017-03-17       Impact factor: 3.738

Review 9.  Trophic activities of endoplasmic reticulum proteins CDNF and MANF.

Authors:  Maria Jӓntti; Brandon K Harvey
Journal:  Cell Tissue Res       Date:  2020-08-26       Impact factor: 4.051

10.  Neurotrophic factor therapy for Parkinson's disease: past, present and future.

Authors:  Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neural Regen Res       Date:  2016-02       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.